Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Canakinumab

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Canakinumab is a therapeutic monoclonal antibody targeting interleukin-1beta (Interleukin-1 (IL-1 / IL-1F2)) beta antagonists (non-natural))
Ridker et al. 2017 N Engl J Med. 377(12): 1119-1131.

…

Antiinflammatory therapy with canakinumab for atherosclerotic disease
Ridker et al. 2017 N Engl J Med. 377(12): 1119-1131.
Canakinumab and Lung Cancer: Intriguing, but Is It Real?
Chabner & Nabel 2018
Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes
De Benedetti et al. 2018 NEJM 378: 1908-1919
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Ridker et al. 2018
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
Ridker et al. 2018 The Lancet 391: 319-328

7/1/2026